There are few effective treatments for advanced ovarian cancer.
A recent study showed that losartan, a drug that lowers blood pressure, could help ovarian cancer treatment.
Every year, more than 20,000 Americans are diagnosed with ovarian cancer.
More than half of them will succumb to the disease. Many cases will not be identified until the disease is in its advanced stages, meaning that it is much more difficult to treat.
Because of this, scientists are looking for new ways to improve ovarian cancer treatment. One approach is to make it easier for chemotherapy drugs to get inside tumor cells.
It is tough for drugs to get into tumor cells
As tumors grow, they build up a stiff, mesh-like structure within them. This “extracellular matrix” surrounds every cell within the tumor. It makes it more difficult for some drugs to get inside the individual tumor cells.
It also increases the overall stiffness of the tumor, squeezing the blood vessels leading into it.
This means that drugs, which are carried in the blood, will have a harder time accessing the interior of the tumor. If a new drug could shrink the extracellular matrix, then chemotherapy drugs could find it easier to enter tumor cells.
Scientists have recently found that a protein called angiotensin II stimulates the build-up of extracellular matrix.
It also causes blood vessels to contract, increasing blood pressure. Because of this, many people with high blood pressure are already taking drugs that inhibit angiotensin II.
A group of researchers in the United States have been studying if losartan, an angiotensin II blocker, can make chemotherapy more effective.
They recently published their results in the Proceedings of the National Academy of Sciences of the United States of America.
Losartan helps treat ovarian cancer tumors in mice
The researchers injected ovarian cancer tumor cells into a group of mice.
These cells grow and divide, and in a few days, they formed solid tumors. They then treated the mice with losartan alone, with the chemotherapy drug paclitaxel, or with both paclitaxel and losartan. Losartan by itself had no effect.
Paclitaxel by itself slowed tumor growth, but the combination of paclitaxel and losartan was even more effective.
Tumors in mice treated with both drugs were half the weight compared to tumors in mice that were only treated with paclitaxel.
Do ovarian cancer patients who are taking certain blood pressure drugs live longer?
Many ovarian cancer patients also have high blood pressure, so they would already be taking blood pressure medicine.
The researchers looked at 123 patients with advanced ovarian cancer who had also been taking angiotensin II-limiting drugs. They compared them to 99 advanced ovarian cancer patients who had been taking other types of blood pressure drugs.
Patients taking drugs to control angiotensin II lived, on average, almost twice as long as patients taking other types of blood pressure drugs.
Specifically, patients taking angiotensin II drugs lived an average of 63 months after their diagnosis of ovarian cancer. Patients taking other types of blood pressure drugs survived for an average of 33 months after diagnosis.
Different drugs use different methods to limit angiotensin II activity. Losartan belongs to a group of drugs known as angiotensin II receptor blockers.
Patients taking drugs from this group lived even longer than patients taking other types of angiotensin II-limiting drugs.
Losartan and similar blood pressure drugs may help ovarian cancer treatment
One important limitation of this clinical study was that the study in patients was strictly observational.
In other words, it did not actually confirm that giving losartan to new patients would help with their cancer treatment. For that, it is necessary to set up a new clinical trial that would randomly assign some cancer patients to receive chemotherapy plus angiotensin II blockers.
These patients would be compared to another group receiving chemotherapy alone.
Despite this limitation, the results of this study are extremely promising. It potentially doubled the survival time of patients with advanced ovarian cancer.
Losartan and similar angiotensin II receptor blockers are inexpensive and relatively safe.
An ovarian cancer treatment that helped patients with advanced disease live almost twice as long would be an extremely welcome development.
Written by Bryan Hughes, PhD
Relevant topics that may be of interest to you:
- Effective Ways to Lower High Blood Pressure
- Targeting the Immune Cells to Treat High Blood Pressure
- Do Nitrate-Rich Vegetables Lower High Blood Pressure?
- Effects of Mediterranean Diet on Endothelial Function and Blood Pressure
- Does dietary nitrate help decrease high blood pressure?
- Can a home blood pressure monitor predict disease risk?
- Zhao, Y., Cao, J., Melamed, A., Worley, M., Gockley, A., Jones, D., Nia, H. T., Zhang, Y., Stylianopoulos, T., Kumar, A. S., Mpekris, F., Datta, M., Sun, Y., Wu, L., Gao, X., Yeku, O., del Carmen, M. G., Spriggs, D. R., Jain, R. K. & Xu, L. Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma. Proceedings of the National Academy of Sciences, 201818357 (2019).
- Antihypertension drug losartan may improve treatment of ovarian cancer. Massachusetts General Hospital (January 15, 2019). Accessed at: https://www.massgeneral.org/News/pressrelease.aspx?id=2339